LONDON, UK, 5th December 2007, Curidium Medica plc, (LSE:CUR), a personalized
medicine company focused on bringing the right drug to the right patient,
announced today that it has entered into a strategic partnership with Takeda
Research Investment, Inc. (TRI), the corporate investment arm of Takeda
Pharmaceutical Company, Limited. As part of the agreement TRI will purchase
10,491,803 ordinary shares and warrants for 20 million additional ordinary
shares in the Company.
